المتخصصون في المجالات الطبية

تتوفر أدناه التجارب السريرية الحالية.

306 الدراسات في Cancer
(الدراسات المفتوحة فقط).

تصفية قائمة الدراسات هذه حسب الموقع، والحالة والمزيد.

1. Reduced Dose Hypofractionated Radiotherapy For Indolent Non-hodgkin Lymphoma

   Mankato, Minn., Rochester, Minn., Jacksonville, Fla., La Crosse, Wis., Albert Lea, Minn., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

   The purpose of thisstudy is to evaluate reduction of radiotherapy dose for patients with indolent NHL by conducting a prospective randomized phase 2 study comparing reduced dose hypofractionated ISRT of 9 Gy delivered over 3 fractions (BED 12 Gy) to standard of care 24 Gy delivered over 12 fractions (BED 29Gy), while simultaneously evaluating prognostic value of pre-radiation functional imaging parameters and molecular markers to predict treatment response and failure.

2. A Study Of CGM In GBM

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to compare standard glucose monitoring versus continuous glucose monitoring (CGM) with endocrinology-guided intervention in newly diagnosed glioblastoma (GBM) patients receiving standard-of-care therapy.

3. A Phase I/II, Open-label, Multi-center Trial Of [177Lu]Lu-NeoB In Combination With Capecitabine In Adult Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression On Previous Endocrine Therapy In Combination With A CDK4/6 Inhibito

   Rochester, Minn.

   The purpose of this study is to determine the recommended doses (RD) and dosing regimens of [ 177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary antitumor activity of two different doses/regimens of [177Lu]Lu-NeoB in combination with capecitabine (dose optimization).

4. EF-41/KEYNOTE D58: Phase 3 Study Of Optune Concomitant With Temozolomide Plus Pembrolizumab In Newly Diagnosed Glioblastoma

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

5. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

   Rochester, Minn.

   This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.

6. Wearable Artificial InTelligence For Cardiac Function And Health Monitoring

   Rochester, Minn.

   The purpose of thist study is to find a cost effective CV surveillance of cancer survivors over long periods of time to prevent the risk of progression of HF and related morbidity and mortality. Mobile device-based AI-ECG can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors  and smart watch based surveillance for cardiotoxicity is feasible and reliable.